Neurocrine Biosciences | NBIX - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 7.61B 2.04B 2026-06
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amgen USD 2.08B 570M 2026-03
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Exelixis USD 262.68M 5.01M 2026-06
Gilead Sciences USD -7.53B 10.11B 2026-06
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pfizer USD -653M 5.84B 2026-06
Prothena USD 32.72M 54.3M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Repligen USD 14.15M 12.38M 2026-06
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Teva Pharmaceutical Industries USD -455M 1.21B 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06